№ lp_1_2_18534
File format: docx Character count: 3971 File size: 93 KB
The document outlines the criteria for the implementation of a state-specific preferred drug list for neuropathic pain agents, detailing approval and denial conditions for various treatments.
Year: 2026
Region / City: Missouri, USA
Topic: Neuropathic Pain Agents
Document Type: Proposal
Institution: MO HealthNet
Author: MO HealthNet and Conduent
Target Audience: Healthcare providers and MO HealthNet participants
Approval Period: 1 year
Approval Date: January 20, 2026
Revision Date: May 29, 2013
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
SmartPA Criteria ProposalDrug/Drug Class: Hereditary Angioedema Agents PDL Edit
Year: 2026
Region / City: Missouri
Topic: Hereditary Angioedema Treatment
Document Type: Proposal
Institution: MO HealthNet
Author: MO HealthNet and Conduent
Target Audience: Health professionals and stakeholders in the MO HealthNet program
Effective Period: Starting from May 9, 2019
Approval Date: January 20, 2026
Modification Date: Not specified
Document Status: Revision of Existing Criteria
Context: A proposal outlining the preferred drug list and approval criteria for hereditary angioedema treatment agents within the MO HealthNet program.
SmartPA Criteria ProposalDrug/Drug Class: Antiretroviral Therapy (ART) PDL EditFirst Implementation Date: April 7, 2022Proposed Date: January 20, 2026Prepared For: MO HealthNetPrepared By: MO HealthNet and Conduent
Year: 2026
Region / City: United States
Topic: Antiretroviral Therapy (ART)
Document Type: Proposal
Institution: MO HealthNet
Author: MO HealthNet, Conduent
Target Audience: Healthcare professionals, policymakers, and health program administrators
Effective Period: 2026–
Approval Date: January 20, 2026
Revision Date: April 7, 2022
SmartPA Criteria ProposalDrug/Drug Class: Anticonvulsants, Dravet Syndrome PDL Edit
Year: 2026
Region / City: MO HealthNet
Topic: Dravet Syndrome, Anticonvulsants
Document Type: Proposal
Organization: MO HealthNet
Author: MO HealthNet and Conduent
Target Audience: Healthcare providers, MO HealthNet participants
Effective Period: Ongoing
Approval Date: January 20, 2026
Amendment Date: N/A
Pregabalin CR Submission for Neuropathic Pain Treatment in Adults
Year: 2021
Region / City: Australia
Topic: Neuropathic pain, Pregabalin CR, Pharmaceutical Submission
Document Type: Submission for Pharmaceutical Listing
Organization: Upjohn Australia Pty Ltd
Author: Not specified
Target Audience: Medical Practitioners, Pharmaceutical Regulators
Action Period: Not specified
Approval Date: 10 March 2021
Modification Date: Not specified
Clinical Criteria: Condition must be refractory to other treatments
PBS Indication: Neuropathic pain in adults
Treatment Phase: Initial and continuing
Prescriber: Medical Practitioners, Nurse Practitioners for continuing therapy
Source: Therapeutic Goods Administration (TGA)
Background: Pregabalin CR tablets were registered in Australia in March 2021 for neuropathic pain in adults.
Purpose of Submission: Request for listing pregabalin CR on the PBS for neuropathic pain treatment under the same clinical criteria as pregabalin IR
International Registration Status: Approved in the USA (2017) and Republic of Korea (2018) for neuropathic pain treatment
Requested Listing: Pregabalin CR tablets for inclusion in PBS under a General Schedule (GE)
Special Program on Treating Chronic and Neuropathic Pain Associated with Peripheral Neuropathy – September 1, 2012
Year: 2012
Location: Port St. Lucie, Florida, USA
Topic: Chronic and Neuropathic Pain Management
Document Type: Event Invitation
Organization: Treasure Coast Nurse Practitioner Association
Sponsor: Depomed
Representative: Laurel Briggs
Guest Speaker: Bruce Hendi, R.Ph, DO
Target Audience: Nurse Practitioners
Event Date: September 1, 2012
Event Time: 6:30 PM
Venue: Tutto Fresco, 905 Reserve Blvd
Registration: Required via ENP Network website
SmartPA Criteria ProposalDrug/Drug Class: Hereditary Angioedema Agents PDL Edit
Year: 2026
Region / City: Missouri
Topic: Hereditary Angioedema Treatment
Document Type: Proposal
Institution: MO HealthNet
Author: MO HealthNet and Conduent
Target Audience: Health professionals and stakeholders in the MO HealthNet program
Effective Period: Starting from May 9, 2019
Approval Date: January 20, 2026
Modification Date: Not specified
Document Status: Revision of Existing Criteria
Context: A proposal outlining the preferred drug list and approval criteria for hereditary angioedema treatment agents within the MO HealthNet program.
SmartPA Criteria ProposalDrug/Drug Class: Antiretroviral Therapy (ART) PDL EditFirst Implementation Date: April 7, 2022Proposed Date: January 20, 2026Prepared For: MO HealthNetPrepared By: MO HealthNet and Conduent
Year: 2026
Region / City: United States
Topic: Antiretroviral Therapy (ART)
Document Type: Proposal
Institution: MO HealthNet
Author: MO HealthNet, Conduent
Target Audience: Healthcare professionals, policymakers, and health program administrators
Effective Period: 2026–
Approval Date: January 20, 2026
Revision Date: April 7, 2022
SmartPA Criteria Proposal Drug/Drug Class: NSAIDs PDL Edit
Year: 2026
Region / City: MO HealthNet
Theme: NSAIDs, Pharmacology, Health Policy
Document Type: Proposal
Institution: MO HealthNet, Conduent
Author: MO HealthNet and Conduent
Target Audience: Healthcare Providers, Policy Makers, MO HealthNet Participants
Period of Validity: Indefinite
Approval Date: January 20, 2026
Modification Date: None
SmartPA Criteria ProposalDrug/Drug Class: Anticonvulsants, Dravet Syndrome PDL Edit
Year: 2026
Region / City: MO HealthNet
Topic: Dravet Syndrome, Anticonvulsants
Document Type: Proposal
Organization: MO HealthNet
Author: MO HealthNet and Conduent
Target Audience: Healthcare providers, MO HealthNet participants
Effective Period: Ongoing
Approval Date: January 20, 2026
Amendment Date: N/A
SmartPA Criteria Proposal Drug/Drug Class: Fibromyalgia Agents PDL Edit
Year: 2026
Region / City: Missouri
Theme: Fibromyalgia Treatment
Document Type: Medical Criteria Proposal
Author: MO HealthNet and Conduent
Target Audience: MO HealthNet participants, healthcare providers
Approval Date: January 20, 2026
Period of Validity: Not specified
Change Date: Not specified
SmartPA Criteria Proposal Drug/Drug Class: Alzheimer’s Agents, Acetylcholinesterase Inhibitors, N-Methyl-D-Aspartate Receptor Antagonists & Combinations PDL Edit
Year: 2026
Region / city: Missouri
Document Type: Proposal
Organization: MO HealthNet
Author: MO HealthNet, Conduent
Target Audience: MO HealthNet participants, healthcare providers
Period of validity: Ongoing
Approval Date: January 20, 2026
Revision Date: May 21, 2008
Criteria Status: Revision of Existing Criteria
Topics: ProposalDrugDrug Neuropathic SmartPA